AR065370A1 - HTRA1 MODULATORS - PDZ AND HTRA3 PDZ - Google Patents

HTRA1 MODULATORS - PDZ AND HTRA3 PDZ

Info

Publication number
AR065370A1
AR065370A1 ARP080100656A ARP080100656A AR065370A1 AR 065370 A1 AR065370 A1 AR 065370A1 AR P080100656 A ARP080100656 A AR P080100656A AR P080100656 A ARP080100656 A AR P080100656A AR 065370 A1 AR065370 A1 AR 065370A1
Authority
AR
Argentina
Prior art keywords
pdz
htra1
htra3
modulators
pdz domain
Prior art date
Application number
ARP080100656A
Other languages
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR065370A1 publication Critical patent/AR065370A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gyroscopes (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Digital Transmission Methods That Use Modulated Carrier Waves (AREA)

Abstract

Se proporcionan ligandos optimizados del dominio PDZ de HtrA1 y del dominio PDZ de HtrA3. Tambien moduladores de la interaccion entre el dominio PDZ de HtrA1 y su ligado y entre el dominio PDZ de HtrA3 y su ligado, asi como metodos para laidentificacion y uso de estos moduladores. Reivindicacion 1: un polipéptido aislado que se une específicamente a un dominio PDZ de HtrA1, en la que el polipéptido comprende una secuencia con un triptofano en la posicion 2 con respecto al extremo CTerminal.Optimized ligands of the PDZ domain of HtrA1 and the PDZ domain of HtrA3 are provided. Also modulators of the interaction between the PDZ domain of HtrA1 and its linked and between the PDZ domain of HtrA3 and its linked, as well as methods for the identification and use of these modulators. Claim 1: An isolated polypeptide that specifically binds to a PDZ domain of HtrA1, wherein the polypeptide comprises a sequence with a tryptophan at position 2 with respect to the CTerminal end.

ARP080100656A 2007-02-16 2008-02-15 HTRA1 MODULATORS - PDZ AND HTRA3 PDZ AR065370A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89042807P 2007-02-16 2007-02-16

Publications (1)

Publication Number Publication Date
AR065370A1 true AR065370A1 (en) 2009-06-03

Family

ID=39590928

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100656A AR065370A1 (en) 2007-02-16 2008-02-15 HTRA1 MODULATORS - PDZ AND HTRA3 PDZ

Country Status (6)

Country Link
EP (1) EP2111413A2 (en)
AR (1) AR065370A1 (en)
CL (1) CL2008000493A1 (en)
PE (1) PE20081795A1 (en)
TW (1) TW200846358A (en)
WO (1) WO2008101160A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (en) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN THE BONE MODELING PROCESS
EA201490778A1 (en) 2011-10-14 2014-09-30 Дженентек, Инк. ANTIBODIES AGAINST HtrA1 AND METHODS OF APPLICATION
AU2013293062A1 (en) 2012-07-19 2014-07-24 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
CA3001362C (en) 2015-10-30 2020-10-13 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
EP3423469A1 (en) 2016-03-04 2019-01-09 H. Hoffnabb-La Roche Ag New trifluoromethylpropanamide derivatives as htra1 inhibitors
WO2017148967A1 (en) * 2016-03-04 2017-09-08 F. Hoffmann-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
EP3484859B1 (en) 2016-07-18 2021-09-15 F. Hoffmann-La Roche AG New difluoroketamide derivatives as htra1 inhibitors
EP3504197B1 (en) 2016-08-23 2021-11-17 F. Hoffmann-La Roche AG New trifluoromethylpropanamide derivatives as htra1 inhibitors
WO2018036942A1 (en) 2016-08-23 2018-03-01 F. Hoffmann-La Roche Ag New difluoroketamide derivatives as htra1 inhibitors
WO2018206816A1 (en) * 2017-05-12 2018-11-15 Universität Duisburg-Essen Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors
WO2020083916A1 (en) * 2018-10-22 2020-04-30 University Of Copenhagen Virally expressed inhibitors of pdz domains, such as pick1 and uses thereof
KR20220150313A (en) * 2020-03-06 2022-11-10 유니버시티 오브 코펜하겐 Lipid conjugated peptide inhibitor of PICK1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants

Also Published As

Publication number Publication date
CL2008000493A1 (en) 2008-06-27
EP2111413A2 (en) 2009-10-28
WO2008101160A2 (en) 2008-08-21
WO2008101160A3 (en) 2009-02-19
PE20081795A1 (en) 2009-01-08
TW200846358A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
AR065370A1 (en) HTRA1 MODULATORS - PDZ AND HTRA3 PDZ
AR119754A2 (en) ANTI-FGFR3 ANTIBODIES AND METHODS USING THEM
CL2007002167A1 (en) Indole derived compounds, iap antagonists; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
EA200970737A1 (en) OXABICYCLOPTANES AND OXABICYCLOPTENS
PE20181268A1 (en) A CONJUGATE INCLUDING OXINTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT, AND THE USE OF THE SAME
HN2009000214A (en) PEPTIDOMIMETICS OF SMAC USEFUL AS INHIBITORS OF APOPTOSIS PROTEINS (IAP)
PA8659101A1 (en) USE OF CYANINE COLORS FOR THE DIAGNOST OF PROLIFERATIVE DISEASES
CL2008001656A1 (en) Anti-c3b antibody; pharmaceutical composition comprising it, and its use to prevent or treat a complement-associated disorder; kit containing it.
AR077629A1 (en) SMAC MIMETICO
ES2722300T3 (en) Antibodies that preferentially bind to extracellular domain 4 of CSF1R and its use
CL2011001232A1 (en) Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment
CL2009000260A1 (en) Pcsk9 antagonist comprising a cdr3 domain of the variable region of the light and heavy chain, which inhibits the cellular uptake of ldl, pharmaceutical composition comprising said antagonist, use of this, nucleotide sequence that encodes the antagonist, vector and host cell who understands it.
CL2013000843A1 (en) Isolated antibody or antigen binding fragment thereof that specifically binds to human cd48 and blocks the interaction between human cd48 and a cd48 receptor; pharmaceutical composition that includes it; And its use.
CU20120095A7 (en) PCSK9 ANTAGONISTS
UA109888C2 (en) ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CL2008002539A1 (en) Substituted indole derivative compounds; pharmaceutical composition comprising them; and its use for the treatment of a viral infection
CL2011001255A1 (en) Pharmaceutical combinations comprising an antibody that specifically recognizes cd38 and at least vincristine; and use of the antibody that specifically recognizes cd38 for the treatment of cancer.
AR080795A1 (en) ANTI-LRP6 ANTIBODIES (PROTEIN RELATED TO THE LDL RECEIVER TYPE 6)
CL2008001213A1 (en) Use of compounds derived from pyridin-4-yl-benzene-1,4-diamino substituted by alindole to prepare a medicament for the treatment of a proliferative disorder such as cancer.
PE20080840A1 (en) METHODS FOR ADMINISTERING LONG-LIVED HYPOGLYCEMIANT AGENTS
EA201170288A1 (en) OXABICYCLOPTANES AND OXABICYCLOPTENS
CL2008002369A1 (en) Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
CL2011001078A1 (en) Compounds derived from spirodihydrotetraazabenzoazulene; preparation procedure; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, sexual dysfunction, hypertension, liver cirrhosis and schizophrenia among others.
GT200900204A (en) COMPOSITE CARBON HYDRATION AND IRON COMPOUNDS
CL2012002904A1 (en) Combination or pharmaceutical composition comprising an inhibitor of cell signaling and / or angiogenesis and an aurora kinase inhibitor (aki); pharmaceutical kit that includes it; its use in the treatment of oncological and fibrotic diseases; and substituted indole and pyrimidine compounds.

Legal Events

Date Code Title Description
FB Suspension of granting procedure